Latest Cancer News

Novel Agent Granted Fast Track Designation for Refractory Metastatic Colorectal Cancer (10-23-2014)
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TAS-102, a novel agent currently under investigation for the treatment of refractory metastatic colorectal cancer. According... Continue Reading

FDA Grants Breakthrough Therapy Designation to AP26113 for ALK-Positive NSCLC (10-22-2014)
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to an investigational agent AP26113 for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small... Continue Reading

Adding Cediranib to Olaparib Markedly Improves Progression-Free Survival but Increases Toxicity in Recurrent Platinum-Sensitive Ovarian Cancer (10-21-2014)
The addition of the antiangiogenic agent cediranib to the PARP inhibitor olaparib in women with recurrent platinum-sensitive ovarian cancer improves time to cancer progression and survival. The results... Continue Reading

More Cancer News

Locations

Scarborough Office
100 Campus Drive, Suite 108
Scarborough, Maine 04074-9308
(207) 396-7600
Fax (207) 396-7610
Brunswick Office
81 Medical Center Drive
Suite 1300G
Brunswick, ME 04011
(207) 729-1148
Fax (207)729-2789
Biddeford Office
26 West Cole Road
Biddeford, Maine 04005-9407
(207) 282-0448
Fax (207)286-9126
Sanford Office
27 Industrial Avenue
Sanford, ME 04073
(207)490-7777
Fax (207) 490-7779